Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis

Annals of Internal Medicine

Volumn 124, Issue 8, 1996, Pages 717-725

  Hatala, Rosemarie ^a,b   Dinh, Tuan ^a,d   Cook, Deborah J ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON GENERAL HOSPITAL   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

^d HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT;

ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; IMMUNOCOMPETENCE; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; MORTALITY; NEPHROTOXICITY; NURSING; OTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG ADMINISTRATION SCHEDULE; EAR DISEASES; HUMANS; IMMUNOCOMPETENCE; KIDNEY DISEASES; RISK FACTORS;

EID: 0029887822     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-124-8-199604150-00003     Document Type: Article

References (80)

1. Sanders WE Jr, Sanders CC. Inducible beta-lactamases, clinical and epidemiologic implications for use of newer cephalosporins Rev Infect Dis. 1988, 10 830-8
2. Hooton TM, Blair AD, Turck M, Counts GW. Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics. Antimicrob Agents and Chemother 1984;26 535-8.
3. Barriere SL Aminoglycosides, a reassessment of their therapeutic role Clin Pharm. 1988,7 385-90
4. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients Am J Med 1989,87:540-6
5. Moellering RC Jr. Emergence of Enterococcus as a significant pathogen Clin Infect Dis. 1992,14 1173-6
6. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy importance of the ratio of peak concentration to minimal inhibitory concentration J Infect Dis 1987,155 93-9
7. Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides Clin Pharm 1986,5 319-24
8. Mattie H, Craig WA, Pechere PC. Determinants of efficacy and toxicity of aminoglycosides J Antimicrob Chemother. 1989,24.281-93.
9. French MA, Cerra FB, Plaut ME, Schentag JJ. Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients Antimicrob Agents Chemother. 1981,19.147-52.
10. Lesar TS, Rotschafer JC, Strand LM, Solem LD, Zaske DE. Gentamicin dosing error with four commonly used nomograms JAMA. 1982,248 1190-3
11. Burton ME, Chow MS, Platt DR, Day RB, Brater DC, Vasko MR. Accuracy of Bayesian and Sawchuk-Zaske dosing methods for gentamicin Clin Pharm 1986;5:143-9.
12. Powell SH, Thompson WL, Luthe MA, Stern RC, Grossniklaus DA, Bloxham DD, et al. Once-daily vs continuous aminoglycoside dosing efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin J Infect Dis 1983,147.918-32.
13. Parker SE, Davey PG. Practicalities of once-daily aminoglycoside dosing J Antimicrob Chemother 1993,31 4-8.
14. Gilbert DN. Once-daily aminoglycoside therapy Antimicrob Agents Chemother. 1991,35 399-405
15. Aguado JM. Once-daily (OD) gentamicin (GN) is less toxic for the tubule cells than thrice-daily (TD) dosing [Abstract]. In: Program and Abstracts - Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, October, 1993 Washington, DC: American Society for Microbiology, 1994 1154.
16. de Vries PJ. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections Eur J Clin Microbiol Infect Dis 1990:9 161-8.
17. Gonzalez P, Aguado JM, Martin MA, Fernandez-Chacon T, Ortuno B. Once-daily aminoglycoside dosing [Letter] Lancet. 1993,341:895.
18. Hollander LF, Bahnini J, De Manzini N, Lau WY, Fan ST, Hermansyur K, et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections J Antimicrob Chemother. 1989,23 773-83
19. Maller R, Isaksson B, Nilsson L, Soren L. A study of amikacin given once versus twice daily in serious infections J Antimicrob Chemother. 1988,22. 75-9
20. Maller R, Ahrne H, Holmen C, Lausen I, Nilsson LE, Smedjegard J. Once- versus twice-daily amikacin regimen efficacy and safety in systemic gram-negative infections Scandinavian Amikacin Once Daily Study Group J Antimicrob Chemother 1993;31 939-48.
21. Marik PE, Lipman J, Kobilski S, Scribante J. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother. 1991,28 753-64
22. Mauracher EH, Lau WY, Kartowisastro H, Ong KH, Genato VX, Limson B, et al. Comparison of once-daily and thrice-daily netilmicin regimens in serious systemic infections a multicenter study in six Asian countries. Clin Ther. 1989,11:604-13.
23. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993,341: 335-9
24. Sturm AW. Netilmicin in the treatment of gram-negative bacteremia single daily versus multiple daily dosage. J Infect Dis. 1989;159 931-7
25. ter Braak EW, de Vries PJ, Bouter KP, van der Vegt SG, Dorrestein GC, Nortier JW, et al. Once-daily dosing regimen for aminoglycoside plus β-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med. 1990,89.58-66
26. Tulkens P. Safety and efficacy of aminoglycosides once-a-day, experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory disease. J Drug Dev. 1988,1(Suppl 3).71-82
27. Vanhaeverbeek M, Siska G, Douchamps J, Herchuelz A. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly. Int J Clin Pharmacol Ther Toxicol 1993,31 153-6
28. Maller R, Ahrne H, Eilard T, Eriksson I, Lausen I. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses Scandinavian Amikacin Once Daily Study Group J Antimicrob Chemother 1991,27(Suppl C):121-8
29. Muijsken M, Vreede R, Van Dijk W, Haverkom M, Kaufman L, Derde M. A randomized clinical study of efficacy and safety of once daily versus conventional dosing of netilmicin in patients with severe infections. J Drug Dev 1988,1(Suppl 3) 145-6
30. Gilbert D. Once-daily dosing (OD) of aminoglycoside (AG) is effective and safe for severe bacterial infection [Abstract] In Program and Abstracts - Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994 Washington, DC American Society for Microbiology, 1995 M86
31. Vreede E. Infections by Gram-Negative Bacilli. Humoral Defence of the Host and Antimicrobial Therapy Utrecht Drukkerij Elinkwijk BV; 1988:143-65.
32. Conly JM, Gold W, Shafran SD. Once-daily aminoglycoside dosing 3 new look at an old drug Can J Infect Dis. 1994,5 205-6
33. Nordstrom L, Lerner SA. Single daily dose therapy with aminoglycosides J Hosp Infect. 1991,18(Suppl A):117-29.
34. Hustinx WN, Hoepelman IM. Aminoglycoside dosage regimens Is once a day enough? Clin Pharmacokinet 1993;25 427-32
35. Smith CR, Lipsky JJ, Laskin OL, Hellmann DB, Mellits ED, Longstreth J, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin N Engl J Med. 1980,302 1106-9.
36. Landis JR, Koch GG. The measurement of observer agreement for categorical data Biometrics 1977,33:159-74
37. Oxman AD, Cook DJ, Guyatt GH. Users' guides to the medical literature. VI How to use an overview. Evidence-Based Medicine Working Group JAMA. 1994;272:1367-71.
38. DerSimonian R, Laird N. Meta-analysis in clinical trials Controlled Clin Trials 1986,7.177-88.
39. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment N Engl J Med. 1988;318 1728-33.
40. Petty B, Baumgardner J, Lietman P. Comparison of the renal effects of single vs. thrice daily dosing of tobramycin in healthy volunteers [Abstract] In Proceedings and Abstracts - 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1986. Washington, DC: American Society for Microbiology; 1987:30
41. Pierre C, Blanchet F, Seta N, Chaigne P, Labarre C, Sterkers O, et al. Tolerance of once-daily dosing of netilmicin and teicoplanin, alone or in combination, in healthy volunteers Clin Pharmacol Ther. 1988;44.458-66
42. Verpooten GA, Giuliano RA, Verbist L, Eestermans G, De Broe ME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin Clin Pharmacol Ther 1989,45 22-7
43. Proctor L, Petty B, Thakor R, Lietman P, Glackin R, Shimizu H. A study of potential vestibulotoxic effects of once daily versus thrice daily administration of tobramycin Laryngoscope. 1987;97:1443-9
44. Blaser J. Minor difference in toxicity and kinetics of once (OD) vs thrice (TID) daily dosing of netilmicin [Abstract] In: Proceedings and Abstracts - Interscience Conference on Antimicrobial Agents and Chemotherapy, 1993 Washington, DC American Society for Microbiology, 1994:1153
45. Velluti G, Covi M, Capelli O, Azzolini L, Zanlol P, Visco G, et al. Netilmicin given as a single daily dose in the treatment of lower respiratory tract and other systemic infections. J Drug Dev 1988;1(Suppl 3) 137-43.
46. Nicolau DP. Once-daily aminoglycosides, experience with 500 patients in a hospital-wide program [Abstract] In: Proceedings and Abstracts - Interscience Conference on Antimicrobial Agents and Chemotherapy, 1993 Washington, DC: American Society for Microbiology, 1994:85
47. Vanhaeverbeek M, Siska G, Herchuelz A. Pharmacokinetics of once-daily amikacin in elderly patients [Letter] J Antimicrob Chemother. 1993;31 185-7.
48. Maller R, Emanuelsson BM, Isaksson B, Nilsson L. Amikacin once daily a new dosing regimen based on drug pharmacokinetics. Scand J Infect Dis. 1990;22:575-9.
49. Bourget P, Fernandez H, Delouis C, Taburet AM. Pharmacokinetics of tobramycin in pregnant women. Safety and efficacy of a once-daily dose regimen J Clin Pharm Ther 1991,16 167-76.
50. Chan G. Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity, and ototoxicity DICP. 1989;23 788-93.
51. Kovarik JM, Hoepelman IM, Verhoef J. Once-daily aminoglycoside administration new strategies for an old drug Eur J Clin Microbiol Infect Dis. 1989,8:761-9
52. Pechere JC, Craig WA, Meunier F. Once daily dosing of aminoglycoside, one step forward J Antimicrob Chemother 1991,27(Suppl C):149-52
53. Van der Auwera P. Pharmacokinetic evaluation of single daily dose amikacin J Antimicrob Chemother. 1991,27(Suppl C):63-71
54. Fan ST, Lau WY, Teoh-Chan CH, Lau KF, Mauracher EH. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis J Antimicrob Chemother 1988,22 69-74.
55. Nordstrom L, Cronberg S, Ringberg H, Tjernstrom O, Walder M. Prospective, comparative, randomized clinical study of aminoglycosides given once a day versus three times a day in severe infections In: Ishigami J, ed Recent Advances in Chemotherapy. Proceedings of the 14th International Congress of Chemotherapy, Kyoto, 1985. Tokyo: Univ Tokyo Pr; 1985:2653-4
56. Nordstrom L, Ringberg H, Cronberg S, Tjernstrom O, Walder M. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990;25 159-73
57. Karlowsky JA, Zhanel GG, Davidson RJ, Hoban DJ. Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1994,38:1165-8.
58. Gerber A. Comparison of once-daily versus thrice-daily human equivalent dosing of aminoglycosides, basic considerations and experimental approach. J Drug Dev. 1988,1 (Suppl 3) 17-23.
59. Tulkens PM. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin J Antimicrob Chemother 1991;27(Suppl C) 49-61
60. Mari k PE, Havlik I, Monteagudo FS, Lipman J. The pharmacokinetic of amikacin in critically ill adult and paediatric patients' comparison of once-versus twice-daily dosing regimens J Antimicrob Chemother 1991;27(Suppl C)81-9
61. Giamarellou H, Yiallouros K, Petrikkos G, Moschovakis E, Vavouraki E, Voutsinas D, et al. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections. J Antimicrob Chemother 1991,27(Suppl C):73-9.
62. Mendes da Costa P, Kaufman L. Amikacin once daily plus metronidazole versus amikacin twice daily plus metronidazole in colorectal surgery Hepatogastroenterology. 1992:39 350-4
63. Sturm A. Netilmicin in the treatment of gram-negative septicemia: single daily versus thrice daily dosage J Drug Dev. 1988,1(Suppl 3) 125-8.
64. Jackson GG, Lolans VT, Daikos GL. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis. 1990;162 408-13
65. Watling SM, Dasta JF. Aminoglycoside dosing considerations in intensive care unit patients Ann Pharmacother. 1993;27:351-7
66. Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ. Users' guides to the medical literature IX A method for grading health care recommendations Evidence-Based Medicine Working Group JAMA 1996; 274:1800-4
67. Watling SM, Kisor DF. Population pharmacokinetics development of a medical intensive care unit-specific gentamicin dosing nomogram. Ann Pharmacother 1993,27:151-4.
68. Gibey R, Dupond JL, Alber O, Leconte des Floris R, Henry JC. Predictive value of urinary N-acetyl-beta-D-glucosamindase (NAG), alanine-aminopeptidase (AAP), and beta-2-microglobulin (beta 2M) in evaluation of nephrotoxicity of gentamicin. Clin Chim Acta 1981;116:25-34.
69. Verpooten GA, Giuliano RA, Verbist L, Eestermans G, De Broe ME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin Clin Pharmacol Ther. 1989;45 22-7
70. Garrison MW, Zaske DE, Rotschafer JC. Aminoglycosides another perspective. Ann Pharmacother. 1990,24 267-71.
71. Schentag JJ. Aminoglycosides In: Evans WE, Schentag JJ, Jusko WJ Applied pharmacokinetics: principles of therapeutic drug monitoring San Francisco Applied Therapeutics, 1980:184-5.
72. Edson RS, Keys TF. The aminoglycosides Streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, sisomicin Mayo Clin Proc. 1983,58: 99-102
73. Meyer RD. Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides Am J Med. 1986;80:119-25
74. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, Reitman D, et al. A method for assessing the quality of a randomized control trial Controlled Clin Trials 1981,2 31-49.
75. Emerson JD, Burdick E, Hoaglin DC, Mosteller F, Chalmers TC. An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials Control Clin Trials. 1990,11: 339-52
76. Schutz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials JAMA 1995,273.408-12
77. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA. 1990,263.1385-9.
78. Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. Pharmacoeconomics. 1992,1 20-32
79. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients Antimicrob Agents Chemother. 1995,39.650-5.
80. Vincent Rajkumar S, Koo JM. Once-daily aminoglycoside dosing [Letter] Lancet 1993,341.895